Outcome parameters of transplantation
| Outcome . | No. . |
|---|---|
| Median follow-up (range), mo | 45 (15.5-66.3) |
| Engraftment | 51 (evaluable) |
| Median transplant dose CD34+ × 106/kg (range) | 5.75 (0.37-23.9) |
| Median transplant dose CD3+ × 103/kg (range) | 0.99 (0-297) |
| Patients engrafting neutrophils | 51/51 |
| Median days to ANC 0.5 × 109/L or more (range) | 11 (9-22) |
| Patients engrafting platelets | 47/51 |
| Median days to platelets 20 × 109/L or more (range) | 16 (13-54) |
| Posttransplantation EBV-LPD | 2 |
| GvHD | 8 |
| Acute, grades II-IV | 4/49; 4 overall grade 2 |
| Chronic | 4/43; 1 limited; 3 extensive |
| Relapses | 9 |
| AML CR1 | 2 |
| AML, 2° MDS | 3 |
| ALL CR1 Ph+ | 1 |
| ALL CR2 | 1 |
| NHL | 2 |
| Deaths | 19 |
| Cause of death | |
| Relapse | 8 |
| AML CRI after MDS | 3 |
| AML CR1 | 2 |
| ALL CR2 | 1 |
| Burkitt lymphoma, PR | 1 |
| Diffuse large cell lymphoma, PR | 1 |
| Infection | 8 |
| GVHD and secondary complications | 2 |
| Other, complications of VATS | 1 |
| Outcome . | No. . |
|---|---|
| Median follow-up (range), mo | 45 (15.5-66.3) |
| Engraftment | 51 (evaluable) |
| Median transplant dose CD34+ × 106/kg (range) | 5.75 (0.37-23.9) |
| Median transplant dose CD3+ × 103/kg (range) | 0.99 (0-297) |
| Patients engrafting neutrophils | 51/51 |
| Median days to ANC 0.5 × 109/L or more (range) | 11 (9-22) |
| Patients engrafting platelets | 47/51 |
| Median days to platelets 20 × 109/L or more (range) | 16 (13-54) |
| Posttransplantation EBV-LPD | 2 |
| GvHD | 8 |
| Acute, grades II-IV | 4/49; 4 overall grade 2 |
| Chronic | 4/43; 1 limited; 3 extensive |
| Relapses | 9 |
| AML CR1 | 2 |
| AML, 2° MDS | 3 |
| ALL CR1 Ph+ | 1 |
| ALL CR2 | 1 |
| NHL | 2 |
| Deaths | 19 |
| Cause of death | |
| Relapse | 8 |
| AML CRI after MDS | 3 |
| AML CR1 | 2 |
| ALL CR2 | 1 |
| Burkitt lymphoma, PR | 1 |
| Diffuse large cell lymphoma, PR | 1 |
| Infection | 8 |
| GVHD and secondary complications | 2 |
| Other, complications of VATS | 1 |
EBV-LPD indicates Epstein-Barr virus lymphoproliferative disease; GvHD, graft-versus-host disease; PR, partial remission; and VATS, video-assisted thoracic surgery.